^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Thyroid Gland Anaplastic Carcinoma
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor) +
    Cotellic (cobimetinib) (MEK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

    Excerpt:
    ... Patients with BRAF mutation may be screened for eligibility in cohorts 2, 3, or 4 (in this order of preference) if they do not meet the entry criteria for cohort 1...
    Trial ID:
    NCT03181100
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC).

    Published date:
    05/13/2020
    Excerpt:
    Response rate (RR) in cohort 1 was 71%: CR 1/17 (6%), PR 11/17 (65%), SD 4/17 (23%), 1 never restaged; in cohort 2 RR was 7%: PR 1/14 (7%), SD 7/14 (50%), PD 4/14 (29%), 2 died early.
    DOI:
    10.1200/JCO.2020.38.15_suppl.6514
    Trial ID:
    NCT03181100